Oncaspar Europese Unie - Sloveens - EMA (European Medicines Agency)

oncaspar

les laboratoires servier - pegaspargaza - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - oncaspar je indiciran kot komponenta antineoplastičnega kombiniranega zdravljenja pri akutni limfoblastni levkemiji (all) pri pediatričnih bolnikih od rojstva do 18 let in pri odraslih bolnikih.

Lytgobi Europese Unie - Sloveens - EMA (European Medicines Agency)

lytgobi

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - zdravila z delovanjem na novotvorbe agenti - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Qutavina Europese Unie - Sloveens - EMA (European Medicines Agency)

qutavina

eurogenerics holdings b.v. - teriparatid - osteoporoza - kalcij homeostaza - qutavina is indicated in adults. zdravljenje osteoporoze pri ženskah po menopavzi in pri moških z večjim tveganjem zloma. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. zdravljenje osteoporoze, povezane s trajno sistemsko glukokortikoidnih terapija pri ženskah in moških na povečano tveganje za zlom.

Mekinist Europese Unie - Sloveens - EMA (European Medicines Agency)

mekinist

novartis europharm limited - trametinib - melanoma - antineoplastična sredstva - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 in 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-small cell lung cancer (nsclc)trametinib v kombinaciji z dabrafenib je indiciran za zdravljenje odraslih bolnikov z napredovalim non-small cell lung cancer z braf v600 mutacija.

Atectura Breezhaler Europese Unie - Sloveens - EMA (European Medicines Agency)

atectura breezhaler

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - zdravila za obstruktivne pljučne bolezni, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Paxlovid Europese Unie - Sloveens - EMA (European Medicines Agency)

paxlovid

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Reconval K1 krema 50 ml Slovenië - Sloveens - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

reconval k1 krema 50 ml

fitomenadion (vitamin k1) - krema - fitomenadion (vitamin k1) 50 ml / 1 tuba - druga zdravila za lokalno zdravljenje aken